LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). STA-9090 is a potent, second generation, small molecule Hsp90 inhibitor that has shown strong activity in a broad range of preclinical solid and hematologic cancer models, including models highly resistant to treatment. The chemical structure of STA-9090 is unrelated to the first generation, ansamycin family of Hsp90 inhibitors (e.g., 17-AAG or IPI-504).
